Ontology type: schema:ScholarlyArticle
2006-12-25
AUTHORSKazuharu Kai, Reiki Nishimura, Nobuyuki Arima, Haruhiko Miyayama, Hirotaka Iwase
ABSTRACTBackgroundHormone receptor status has been one of the most important factors in predicting the response to endocrine therapy in breast cancer patients. However, half of those patients with estrogen receptor-positive tumors do not respond to endocrine therapy. There have been no universal factors for predicting resistance to endocrine therapy in this population. Recently, p53 status has been extensively used as a predictive factor for response to systemic therapy, because tumor cells lacking p53 function do not respond to systemic therapy due to a failure in apoptosis. We therefore studied the relationship between the efficacy of endocrine therapy and biological factors, including p53.MethodsThe expression of p53, Ki67, and human epidermal growth factor receptor (HER)2 was examined by immunostaining in the primary tumors of 53 patients who received endocrine therapy for recurrent or advanced breast cancer. The following clinical factors were also analyzed: site treated, disease-free interval, and response to first-line endocrine therapy. To evaluate the significance of these factors, time to endocrine therapy failure (TTEF), or the total duration of sequential endocrine therapies was adopted as representing the clinical outcome.ResultsThe median TTEF was 16.1 months (range, 2.5–89.9 months). Multivariate analysis showed significantly reduced TTEF associated with no response to first-line endocrine therapy (P = 0.006 and P = 0.002 in all patients and in recurrent patients, respectively) and associated with positive p53 expression (P = 0.066 and P = 0.004, respectively).Conclusionp53 expression status was a significant molecular marker as well as the response to first-line endocrine therapy for predicting TTEF in recurrent breast cancer with hormone-sensitive disease. More... »
PAGES426-433
http://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6
DOIhttp://dx.doi.org/10.1007/s10147-006-0601-6
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1001769831
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/17180510
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents, Hormonal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biomarkers, Tumor",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cohort Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Resistance, Neoplasm",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Estrogen Receptor Modulators",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Immunoenzyme Techniques",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Recurrence, Local",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Estrogen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Progesterone",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Soft Tissue Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Rate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Failure",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tumor Suppressor Protein p53",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan",
"Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Kai",
"givenName": "Kazuharu",
"id": "sg:person.01167266271.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167266271.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Nishimura",
"givenName": "Reiki",
"id": "sg:person.013173055502.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Arima",
"givenName": "Nobuyuki",
"id": "sg:person.016542450374.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Miyayama",
"givenName": "Haruhiko",
"id": "sg:person.01312777604.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312777604.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.274841.c",
"name": [
"Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Iwase",
"givenName": "Hirotaka",
"id": "sg:person.01117473535.84",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/bf00311752",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000805186",
"https://doi.org/10.1007/bf00311752"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1385/endo:13:1:1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003856049",
"https://doi.org/10.1385/endo:13:1:1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1995.497",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045270804",
"https://doi.org/10.1038/bjc.1995.497"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nm1095-1029",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017425364",
"https://doi.org/10.1038/nm1095-1029"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1996.6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044599284",
"https://doi.org/10.1038/bjc.1996.6"
],
"type": "CreativeWork"
}
],
"datePublished": "2006-12-25",
"datePublishedReg": "2006-12-25",
"description": "BackgroundHormone receptor status has been one of the most important factors in predicting the response to endocrine therapy in breast cancer patients. However, half of those patients with estrogen receptor-positive tumors do not respond to endocrine therapy. There have been no universal factors for predicting resistance to endocrine therapy in this population. Recently, p53 status has been extensively used as a predictive factor for response to systemic therapy, because tumor cells lacking p53 function do not respond to systemic therapy due to a failure in apoptosis. We therefore studied the relationship between the efficacy of endocrine therapy and biological factors, including p53.MethodsThe expression of p53, Ki67, and human epidermal growth factor receptor (HER)2 was examined by immunostaining in the primary tumors of 53 patients who received endocrine therapy for recurrent or advanced breast cancer. The following clinical factors were also analyzed: site treated, disease-free interval, and response to first-line endocrine therapy. To evaluate the significance of these factors, time to endocrine therapy failure (TTEF), or the total duration of sequential endocrine therapies was adopted as representing the clinical outcome.ResultsThe median TTEF was 16.1 months (range, 2.5\u201389.9 months). Multivariate analysis showed significantly reduced TTEF associated with no response to first-line endocrine therapy (P = 0.006 and P = 0.002 in all patients and in recurrent patients, respectively) and associated with positive p53 expression (P = 0.066 and P = 0.004, respectively).Conclusionp53 expression status was a significant molecular marker as well as the response to first-line endocrine therapy for predicting TTEF in recurrent breast cancer with hormone-sensitive disease.",
"genre": "article",
"id": "sg:pub.10.1007/s10147-006-0601-6",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1312225",
"issn": [
"1341-9625",
"1437-7772"
],
"name": "International Journal of Clinical Oncology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "11"
}
],
"keywords": [
"first-line endocrine therapy",
"endocrine therapy",
"recurrent breast cancer",
"breast cancer",
"systemic therapy",
"therapy failure",
"significant molecular markers",
"expression status",
"estrogen receptor-positive tumors",
"sequential endocrine therapy",
"hormone-sensitive disease",
"human epidermal growth factor receptor",
"disease-free interval",
"advanced breast cancer",
"positive p53 expression",
"receptor-positive tumors",
"breast cancer patients",
"p53 expression status",
"epidermal growth factor receptor",
"growth factor receptor",
"receptor status",
"clinical factors",
"cohort study",
"clinical outcomes",
"predictive factors",
"cancer patients",
"primary tumor",
"p53 expression",
"therapy",
"multivariate analysis",
"patients",
"tumor cells",
"factor receptor",
"cancer",
"total duration",
"p53 function",
"tumors",
"status",
"molecular markers",
"p53",
"markers",
"failure",
"biological factors",
"response",
"factors",
"Ki67",
"expression",
"disease",
"recurrent",
"months",
"receptors",
"efficacy",
"outcomes",
"apoptosis",
"duration",
"important factor",
"cells",
"population",
"intervals",
"half",
"significance",
"study",
"time",
"resistance",
"function",
"universal factor",
"sites",
"relationship",
"analysis"
],
"name": "p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study",
"pagination": "426-433",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1001769831"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10147-006-0601-6"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"17180510"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10147-006-0601-6",
"https://app.dimensions.ai/details/publication/pub.1001769831"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:05",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_430.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s10147-006-0601-6"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'
This table displays all metadata directly associated to this object as RDF triples.
277 TRIPLES
22 PREDICATES
123 URIs
109 LITERALS
29 BLANK NODES